A Study to Evaluate the Efficacy of ELAPR in Women With Striae Distensae Alba

Striae Distensae Clinical Trial

Official title:

A Randomized, Within-Subject, Placebo-Controlled, Single-Blind Study to Evaluate the Efficacy of ELAPR002f and ELAPR002g in Women With Striae Distensae (SD) Alba

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02510768
• Other study ID #: ELAPR-P1C
• Status: Completed
• Phase: Phase 1
• Start date: April 16, 2015
• Est. completion date: March 6, 2018

Study information

• Verified date: June 2018
• Source: Elastagen Pty Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is designed to evaluate the efficacy of two formulations of a cross-linked tropoelastin matrix given the product codes ELAPR002f and ELAPR002g (collectively referred to as ELAPR or ELAPR002) for the treatment of Striae Distensae (SD) alba when administered as intradermal implants.

Description:

The study will consist of six study visits. There will be a screening visit to confirm eligibility and to assess baseline parameters (Day -28 to Day -1). For enrolled subjects there will be three intradermal (i.d.) treatment sessions of ELAPR002f or ELAPR002g and placebo, given at one-monthly intervals (approximately Day 0, Day 28 and Day 56). There will be a safety assessment visit 7 days after the first treatment session (Day 7) to review any adverse events and assess the implant sites. ELAPR002f or ELAPR002g will be administered alone vs. placebo. Subjects will be followed for a total of 12 weeks (to Day 84) following the first treatment, with efficacy and safety assessments undertaken at each study visit. At the final follow-up visit (Day 84) a biopsy sample will be taken from each of the treated SDs (active and placebo treated), together with a control biopsy of normal skin collected from an area of the lateral aspect of the abdomen, hip or thigh without an SD alba. Each study subject will act as their own control with active and placebo treatments given single-blind to contralateral sides of the abdomen, hip or thigh, into matched and paired SD. Prior to administration the selected injection sites along the length of SD alba to be treated will be identified and marked with a semi-permanent mark to ensure consistency of anatomic sites for treatment and biopsy. Follow-up period extended to D168, D336 and D504.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: March 6, 2018
• Est. primary completion date: October 3, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 30 Years to 55 Years

Eligibility

Inclusion Criteria:

• Female subjects with at least four abdominal, hip or thigh SD alba which are approximately bilaterally symmetrical (similar dimensions/location/colour) and are of at least 6 cm in length and no more than 5mm wide.

• SD alba within an area of skin of otherwise normal, smooth, mainly flat appearance.

• Age: 30 - 55 years.

• BMI: 18.5 to 35.0 Kg/m2.

• Capable of providing voluntary informed consent.

• Good general health.

• Female subjects who are sexually active will be of non-child bearing potential (i.e., surgically sterilized or postmenopausal), abstain from sexual intercourse, or use a reliable method of contraception (e.g. hormonal contraceptive, condom, IUD) for at least 30 days prior to dosing and during the duration of the study.

• Fitzpatrick skin types II, III or IV.

Exclusion Criteria:

• SD alba within an area of otherwise abnormal skin appearance including unusual lumpiness or abnormal skin laxity.

• Current or previous medical or surgical treatment of SD.

• Known hypersensitivity to tropoelastin, hyaluronic acid or any other component of ELAPR002f or ELAPR002g.

• Female subjects with a positive pregnancy test, women refusing to agree to adequate contraception and pregnancy tests during the study, or women who are planning to become pregnant during the period of the trial.

• Participation in a clinical trial of a pharmacological agent within 1 month prior to screening.

• Clinically significant haematology or biochemistry findings at screening.

• Positive test for hepatitis B, hepatitis C or HIV at screening.

• Bleeding diathesis, anticoagulant drugs, thrombocytopenia or clinically significant prolonged activated partial thromboplastin time (APTT) or prothrombin time (PT).

• Chronic use of aspirin, other non-steroidal anti-inflammatory drugs or other anti-platelet agents.

• History of keloid formation.

• Systemic corticosteroids within last 12 weeks.

• Diabetes or other metabolic disorders that may interfere with the subject's response to treatment in the opinion of the investigator.

• Any serious medical condition which in the opinion of the investigator would have a strong possibility of requiring systemic corticosteroid medication.

• Females who are pregnant or lactating.

• Previous administration of tropoelastin.

• A history of anaphylaxis or allergic reactions including any known hypersensitivity to lidocaine.

• Use of any investigational product on the intended implant site in the previous 12 months.

• Fitzpatrick skin types I, V or VI.

• Any other factor that in the opinion of the Investigator would make the subject unsafe or unsuitable for the study.

Related Conditions & MeSH terms

• Striae Distensae

Intervention

Device:
• ELAPR002f
Intradermal implant
• ELAPR002g
Intradermal implant
• Saline
Intradermal implant

Locations

Country	Name	City	State
United Kingdom	Hammersmith Medicines Research	London

Sponsors (1)

Lead Sponsor	Collaborator
Elastagen Pty Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Size of SD alba scars pre and post treatment.	Measurement of scar dimensions pre and post treatment (width x length x depth in mm) as measured by 3D photography, also 2D photography, subject satisfaction and biopsy (histology).	3 months
Secondary	Frequency and severity of implant site reactions post treatment.	Measure incidence and severity of implant site reactions as assessed by clinical observation and subject diary card records.	3 months